SORT BY

FILTER BY

also on other fortune lists

company facts

g500 stats

Global 500

Courtesy of Merck

246

Merck

MRK

U.S.

Revenue for the 165-year-old drug maker slid 6.5% in 2015 largely due to currency fluctuations and divestitures. In the U.S., sales grew on the strong performance of its diabetes and cancer medications and as a result of its $8.3 billion acquisition of antibiotic maker Cubist Pharmaceuticals. The company also pressed ahead with restructuring efforts–it shed 2,000 jobs in 2015–and kept pace in the industry immunotherapy race, with the widening range of approved uses for Keytruda, Merck’s breakthrough immuno-oncology drug.

CEO

Kenneth C. Frazier

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, NJ

Employees

68,000

Years on Global 500 List

22

Key Financials (last fiscal year)
($ Millions)% change
Revenues ($M)$39,498-6.5%
Profits ($M)$4,442-62.7%
Assets ($M)$101,779
Total Stockholder Equity ($M)$44,676
Profit Ratios
Profit as % of Revenues11.2%
Profits as % of Assets4.4%
Profits as % of Stockholder Equity9.9%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

Pfizer's Costly Divorce: The Pharma Giant Says Brexit Will Cost It $100 Million

The break threatens to slow goods at borders that are now wide open and force companies to duplicate regulatory efforts.

Read More →
The Health Care Companies Changing the World

Why Merck, Johnson & Johnson, Humana, and others made our crop of firms doing well by doing good.

Read More →
Deploying the Profit Motive to Beat Ebola

An example of the problem-solving powers of business, from Fortune’s Change the World list.

Read More →

Videos about Merck

Donald Trump Just Lost the Support of More CEOs

This time over his muted response to violence in Charlottesville.

Read More →